Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1159 | Educational outreach Wiki | 1.00 |
| drug342 | Audit and Feedback Wiki | 1.00 |
| drug792 | Ciclesonide Wiki | 0.71 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The primary objective is to measure the feasibility, acceptability, and appropriateness of audit and feedback with educational outreach as a strategy to align continuous pulse oximetry use in stable bronchiolitis patients with evidence and guideline recommendations.
Description: The participant rates the feasibility of the intervention based on 4 statements, with 5 options for each statement ranging from (1) Completely Disagree to (5) Completely Agree.
Measure: 4-item Feasibility of Intervention Measure (FIM) Time: 6 monthsDescription: The participant rates the acceptability of the intervention based on 4 statements, with 5 options for each statement ranging from (1) Completely Disagree to (5) Completely Agree.
Measure: 4-item Acceptability of Intervention Measure (AIM) Time: 6 monthsDescription: The participant rates the appropriateness of the intervention based on 4 statements, with 5 options for each statement ranging from (1) Completely Disagree to (5) Completely Agree.
Measure: 4-item Intervention Appropriateness Measure (IAM) Time: 6 monthsDescription: Continuous pulse oximetry use rates in children with bronchiolitis who are not requiring supplemental oxygen administration.
Measure: Continuous pulse oximetry use rates Time: 6 monthsDescription: This measure will be calculated using chart review (to determine presence of electronic health record data from the medical monitoring device) and direct observation (to determine actual monitoring at the bedside).
Measure: Sensitivity of the presence of electronic health record data from the medical monitoring device for actual monitoring at the bedside in bronchiolitis. Sensitivity is also referred to as the "true positive rate." Time: 6 monthsDescription: This measure will be calculated using chart review (to determine presence of electronic health record data from the medical monitoring device) and direct observation (to determine actual monitoring at the bedside).
Measure: Specificity of the absence of electronic health record data from the medical monitoring device for absence of monitoring at the bedside in bronchiolitis. Specificity is also referred to as the "true negative rate." Time: 6 monthsDescription: This measure will be calculated using chart review (to determine presence of electronic health record data from the medical monitoring device) and direct observation (to determine actual monitoring at the bedside).
Measure: Positive predictive value of the presence of electronic health record data from the medical monitoring device for actual monitoring at the bedside in bronchiolitis. Time: 6 monthsDescription: This measure will be calculated using chart review (to determine presence of electronic health record data from the medical monitoring device) and direct observation (to determine actual monitoring at the bedside).
Measure: Negative predictive value of the absence of electronic health record data from the medical monitoring device for absence of monitoring at the bedside in bronchiolitis. Time: 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports